echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Food Articles > Agilent Honors Professor Antoni Ribas with the Thought Leader Award

    Agilent Honors Professor Antoni Ribas with the Thought Leader Award

    • Last Update: 2022-09-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Agilent has awarded the Thought Leader Award to Professor Antoni Ribas, a distinguished melanoma physician-researcher for his research in cancer genomics and immunotherapy.

    April 25, 2019, Beijing - Agilent Technologies, Inc.
    (NYSE: A) has announced that it has awarded Professor Antoni Ribas the Agilent Thought Leadership Award for his research in genomics and immunotherapy
    .
    Dr.
    Ribas is a renowned oncologist who is currently using next-generation genomics solutions to identify the mechanisms and biomarkers associated with resistance and response in patients treated with immunotherapy for melanoma
    .

    Dr.
    Ribas is Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA)
    .
    He is also director of the Tumor Immunology Program at the UCLA Jonsson Comprehensive Cancer Center and the UCLA Parker Institute for Cancer Immunotherapy (PICI) Center
    .

    Dr.
    Ribas said: "I am honored to receive this award, which gives me the opportunity to further study this deadliest form of skin cancer
    .
    By partnering with Agilent, my laboratory will be better equipped to conduct research that will help many Develop new treatment strategies for patients who do not respond well to therapy
    .
    "

    Kamni Vijay, vice president and general manager of Agilent's Genomics Group, said: "Agilent is proud to partner with leading researchers such as Dr.
    Ribas to help us gain insights into how patients respond to immunotherapy
    .
    In a rapidly evolving field, new discoveries about resistance and response mechanisms could lead us to discover more biomarkers and ultimately better treatments for patients
    .
    "

    Vijay noted that these biomarkers could further influence patients' choice of immunotherapy treatment options and could help scientists identify new, alternative drug targets
    .

    The Agilent Thought Leaders Program provides research funding, products and expertise for the research of authoritative thought leaders in life sciences, diagnostics and chemical analysis, which will undoubtedly promote great progress in basic science
    .
    For information on previous recipients, visit the Agilent Thought Leaders Program website
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.